ARTICLE | Clinical News
Eribulin mesylate regulatory update
March 7, 2016 8:00 AM UTC
Eisai said Japan approved Halaven eribulin mesylate to treat soft tissue sarcoma (STS). The synthetic analog of halichondrin B is approved in Japan to treat unresectable or recurrent breast cancer. Ha...